Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533259 | 0.77 | MAPT (0.50) | HRH4HTR3ACYP2D6CYP2C9SIRT6 | |
| SCHEMBL609738 | 0.73 | SIRT6 (0.45) | HRH4HTR3ACYP2D6CYP2C9SIRT6 | |
| SCHEMBL17222802 | 0.71 | MAPT (0.52) | HTR3ACYP2D6CYP2C9SIRT6SMN1; SMN2 | |
| SCHEMBL21855206 | 0.71 | HRH4 (0.49) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL29190610 | 0.70 | HRH4 (0.58) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL29190540 | 0.70 | HRH4 (0.62) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14814864 | 0.69 | KDM4E (0.40) | KDM4EKMT2A | |
| SCHEMBL854731 | 0.69 | MAPT (0.74) | CYP2C9SIRT6KDM4EKMT2A | |
| SCHEMBL30464683 | 0.69 | MAPT (0.74) | CYP2C9SIRT6KDM4EKMT2A | |
| SCHEMBL15770595 | 0.69 | MAPT (0.52) | CYP2D6CYP2C9SIRT6KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | HRH4 825/4885HTR3A 1471/4885CYP2D6 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.